
|Articles|April 27, 2012
AstraZeneca C.E.O. to Step Down
Advertisement
David Brennan, the chief executive of AstraZeneca, will step down on June 1 as the big British pharmaceutical company struggles with competition from makers of generic drugs and the failure of several drug development projects.
Mr. Brennan, 58, who has been in his post for six years, was under some pressure from shareholders to resign because of AstraZeneca’s performance.
Read the full story:
Source: The New York Times
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Multiagonists Outpace Older GLP-1 Drugs for Weight Loss
2
Inside Myeloma’s Evolution From Death Sentence to Cure
3
Evolocumab Cuts Death Risk for a First Heart Attack or Stroke
4
Better Cardiovascular Health Tied to Lower Overactive Bladder Risk
5




